Harpoon CEO resigns in wake of dwindling market cap and sliding stock price
Bleeding market cap since the start of June, Harpoon Therapeutics has found itself in the midst of a CEO transition.
Jerry McMahon is resigning from his president and chief executive posts, Harpoon announced after the closing bell Tuesday, as the company hopes to move past a months-long slide that’s seen $HARP shares fall nearly 70%. McMahon will be succeeded by Julie Eastland, the COO and CFO of ReCode Therapeutics, effective Nov. 8.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.